The Lyt-2 molecule recognizes residues in the class I alpha 3 domain in allogeneic cytotoxic T cell responses by unknown
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T cell recognition of foreign class I antigens involves an interaction between the
TCR a and 0 chains and the polymorphic amino acids of the al and a2 domains
of the class I antigen . The three-dimensional structure of a human class I antigen
has recently been determined and suggests that residues from the al and a2 do-
that are recognized by the TCR are clustered on top of the molecule and
the recognition site for processed antigens (1, 2) . Residues from the0 do-
ibute to this recognition site, which is consistent with
CTL do not recognize polymorphic residues
omain (3-5) .
is considerable evidence suggesting that in addition to the TCR, several
"accessory" molecules on the T cell surface facilitate interaction with a target cell .
Among these accessory molecules are Lyt-2 (CD8), which facilitates the reactivity
ofT cells with class IMHC molecules, and L3T4 (CD4), which performs a similar
role for class II-reactiveT cells . The experimental observations that implicate these
accessory molecules in T cell recognition come from systems in which antibodies
to Lyt-2 or L3T4 inhibit the function of class I- or class II-reactive T cells, respec-
tively (6-8) . More recently it has been demonstrated that transfection of the Lyt-
2/CD8 gene, as well asTCRa and -0 genes, is necessary to confer reactivity to class
I determinants in a recipient cell (9, 10). It has been suggested that the Lyt-2 mole-
cule binds to a determinant expressed on all class I molecules on the target cell,
thereby facilitating interaction between the effector and target cells (11, 12) . This
determinant would be conserved, or monomorphic ; however, the nature of this de-
terminant has yet to be defined.
The ability ofmAb to the class I a3 domain to block CTL function (3) as well
as the characterization of a somatic cell mutant that expresses an alteration in the
ofH-2D' (13) have raised the possibility that residues in the a3 domain
of class I molecules are recognized by CTL . The nature of the mutation
H-2Dd gene has been identified and reproduced in a cloned gene by oligonucleo-
tide mutagenesis (14). Cells transfected with thismutant gene are not killed by anti-
Dd-reactive CTL generated in a primary in vitro response . In this paper, we pro-
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vide evidence that residues in the a3 domain of class I molecules on the target cell
contribute to a conserved determinant that is recognized by the Lyt-2 molecule on
CTL . Several lines of evidence support this conclusion : (a) mAbs to determinants
in the a3 domain ofH-2Ld or H-21)d inhibit the generation ofprimary CTL in vitro
but do not inhibit the generation ofand only partially inhibit the function of sec-
ondaryCTL ; (b) secondaryCTL populations generated in the presence ofantibodies
specific for the a3 domain of the stimulating antigen, in contrast to primary or sec-
ondary CTL generated in the absence ofmAb, are only weakly inhibited by anti-
body to Lyt-2 ; (c) treatment of mice with graft-specific antibodies to both a3, as well
as al/a2 domain determinants is necessary to enhance the survival of skin grafts ;
(d) target cells expressing a mutant H-2Dd molecule that possesses a single amino
acid substitution in the a3 domain are not killed by CTL generated in a primary
in vitro response, but are killed by the Lyt-2-independent CTL population gener-
ated by secondary stimulation in the presence of antibody to the a3 domain of H-
2Dd ; and (e) cells expressing the a3 mutant Dd molecule fail to elicit a primary in
vitro cytotoxic response. In total, these results identify residues in the class I a3 do-
main that are involved in Lyt-2 recognition and furthermore suggest that mAbs to
determinants in the a3 domain can be used in vivo and in vitro to block this Lyt-2-
dependent recognition .
Materials and Methods
Mice.
￿
BALB/cKh (Kd, Dd, Ld), BALB/c-H-2dms (Kd, Dd), C3H (Kk, Dk), and(C3H.OL
(Kd, D k) x BALB.K (Kk , Dk))Fl were bred in the animal facility ofDr . Donald C . Shreffler,
Washington University School of Medicine, St . Louis, MO.
Antibodies.
￿
The mAbs used have been previously described . Briefly, antibody 30-5-7 was
derived in dm2 mice and was shown to recognize an epitope in the al/a2 domain of L d,
whereas antibody 28-14-8 was derived from C3H mice and was shown to recognize the a3
domain of Ld and several other D region-encoded molecules (15, 16) . Antibodies 34-5-8 and
34-2-12 were both derived from C3H mice and were shown to recognize the al/a2 and a3
domains of Dd, respectively (16, 17) . Antibody 3-83 was derived from BALB/c and recog-
nizes H-2k antigens (18) . All five of the above mAbs have the y2a isotype and when grown
as an ascites contained a titer of antibody of "30,000, as measured by dye-exclusion cytotox-
icity (data not shown) . They also have comparable affinities based on analysis by flow
microfluorometry (FMF) . 1 The mAbs 53-6.7 and 53-7.3 were both derived from the rat, have
the y2a isotype, and recognize Lyt-2 and Lyt-1, respectively (19) . All antibodies were ana-
lyzed byFMF on splenicT cells and/or target celllines and were titered inCTL assays before
use in the experiments reported here.
Skin Grafting.
￿
Skin grafts were performed as described previously (20) . Full thickness donor
tail skin grafts were trimmed to -0.5 x 1.0 cm . Appropriately sized graft beds were pre-
pared on the recipient's dorsal thorax by carefully removing skin with scissors without dis-
turbing the panniculus carnosus . All grafts were male to male . The transplanted tissues were
protected with a gauze dressing and a plaster bandage for 7 d . Grafts were scored as rejected
when <10% of the donor tissue was viable by gross inspection .
Culture ofCell Lines.
￿
All ofthe cell lines used as targets were grown inDME (high glucose)
supplemented with L-glutamine, pyruvate, and 10% FCS . P815 is a mouse mastocytoma iso-
lated from a DBA/2 mouse . R8.15.28 (Dd glu) and L.Dd.28 express the transfected wild-type
Dd gene and R8.15.29 (Dd lys) and L.Dd .29 express the transfected a3 mutant Dd gene as
previously described (14) . The R8.15 cell line into which the genes were transfected was iso-
I Abbreviations used in this paper: dm2, Ld loss mutant mouse strain BALB/c-H-2dm2 ; FMF, flow
microfluorometry.CONNOLLY ET AL.
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lated from R8 (H-2d x H-24)F, by immunoselection and does not possess H-2d genes (21).
The L.Dd.28 and L.Dd.29 cell lines were produced by transfection into L cells, a fibroblast
cell line originating in C3H (H-2') mice. The R8.15 transfected cell lines were cultured in
the presence of 400 ug/ml G-418 sulfate antibiotic (Sigma Chemical Co., St. Louis, MO)
and the L cell-transfected cell lines were cultured in the presence of 200 jig/ml G-418 sulfate
antibiotic. Cells were used for targets during log phase of growth.
Fluorescence LabelingofCellsandAnalysis byFMF .
￿
For fluorescence analysis, cells were washed,
labeled, and analyzed in HBSS lacking phenol red but containing 0.2% BSA and 0.1% so-
dium azide (FMF medium). 4 x 105 cellswere placed in each well of a round-bottomed mi-
crotiter plate (Flow Laboratories, Inc., McLean, VA), washed two times, and incubated for
30 min at 4'C in the presence of a saturating concentration of mAb. The cellswere washed
two times and resuspended in a saturating concentration of fluorescein-conjugated, affinity-
purified F(ab')2 fragment of goat anti-mouse IgG, Fc specific, or of goat anti-rat IgG
(CooperBiomedical, Inc., Malvern, PA). The cells were incubated for 30 min at 4°C then
washed three times and resuspended in FMF medium containing 10 Rg/ml propidium io-
dide, used to exclude dead (red fluorescent) cells from analysis.
Cellswere analyzed on a FRCS IV (Becton &Dickinson Co., Mountain View, CA) equipped
with an argon ion laser tuned to 488 nm and operating at 300 mW of power. Fluorescence
histograms were generated with logarithmic amplification of fluorescence emitted by single
viable cells. Each sample analyzed comprised a minimum of 5 x 104 cells. Cells labeled with
only the fluorescein-conjugated antibody were always included as controls.
Generation ofH-2Ls- or H-21)4-sped CTL.
￿
Responding spleen cells (7.5 x 106) were cocul-
tured with stimulating spleen cells (3.5 x 106, 2,000 rad), L cells (5 x 104, 10,000 rad) or
medium alone in 24-well Linbro trays(Flow Laboratories, Inc.) containing 2 ml RPMI 1640
medium (Mediatech, Washington, DC) supplemented with L-glutamine, sodium pyruvate,
nonessential amino acids, penicillin, streptomycin, 5 x 10-5 M ß-mercaptoethanol, and 10%
FCS (HyClone Laboratories, Logan, UT). After 5 d at 37°C in the presence of 5ojo C02,
effector cells were harvested, washed, and resuspended in RPMI 1640 medium supplemented
with 10% FCS (RPMI-FCS). For those experiments that included mAbs during the 5-d sen-
sitization, 10' stimulator spleen cellswere preincubated with 500 1r1 ofmAb ascites (1 :10 di-
lution in culture medium) for 30 min on ice. They were washed and resuspended in fresh
medium containing the appropriate antibody before addition to the culture wells. The final
concentration of antibody in the culture was 1%.
"Cr-release Assay.
￿
3 x 106 target cells were labeled with 150-300 gCi of"Cr (Na5'CrO4,
10-25 mCi/ml; Amersham Corp., Arlington Heights, IL) in 300 wl of RPMI-FCS for 45
min at 37 °C in 5% C02. Cells were washed twice and 104 cells were added to the wells of
round-bottomed microtiter plates. For antibody blocking studies, 50 Rl of antibody was prein-
cubated with 50 ul of target cells or 100 wl of effector cells or medium for 20 min at 37°C.
The remaining cells were added to a final volume of 200 pl per well, the plates were spun
at 50 g for 1 min and incubated in a humidified atmosphere at 37°C, 5% C02. At the end
of 4 h the plates were spun at 800 g for 5 min and 100 ul of supernatant was counted in a
Searle automatic gamma counter (Searle Analytic, Des Plaines, IL). The mean of triplicate
samples was calculated and percent 5'Cr release was determined according to the following
equation: Percent "Cr release = 100 x [(experimental "Cr release - control "Cr re-
lease)/(maximum "Cr release - control 51Cr release)], where experimental "Cr release
represents counts from target cellsmixed with effector cells, control "Cr release represents
counts from target cells incubated in medium alone (spontaneous release), and maximum
"Cr release represents counts from target cells exposed to 5% Triton-X100. For the data
presented in this paper the SEM percent specific lysis was <5% of the value of the mean.
Results
Antibody to the 0 Domain of H-2Ld Inhibits Lysis by Primary, but not Secondary, CTL
lbpulations. To delineate the involvement of the different domains of class I molecules
in CTL recognition, we examined the ability of antibodies specific for either the100
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al/a2 or the a3 domain to inhibit lysis by Ld-specific CTL. Spleen cells from
BALB/c-H-2 1'" 2 (dm2) mutant mice that have undergone a deletion of the Ld gene
(22) were stimulated in vitro with spleen cells from BALB/c mice . Antibodies to
either the al/a2 (30-5-7) or the a3 (28-14-8) domain strongly inhibited lysis of target
cells by these Ld-specific CTL derived by primary in vitro stimulation (Fig . 1 A) .
We next examined whether these same antibodies would inhibit anti-LdCTL gener-
ated ina secondary response .Dm2 mice were primed in vivo by grafting ofBALB/c
skin . 1-2 wk after rejection, spleen cells from these mice were restimulated in vitro.
Although we refer to this population as secondary CTL, it is possible that some
unprimedT cells are also stimulated and thereforesome primaryCTLmaybe present.
Lysis ofLd-positive targets by this secondary CTL population was inhibited by the
30-5-7, but not the 28-14-8 antibody (Fig. 1 B) . There are several explanations for
the inhibition ofCTLfunction by antibodies including: (a) binding of the antibody
createsasteric hindrance forCTLrecognitionand/or killing, (b)bindingofthe anti-
body alters theconformation ofallodeterminants recognized by CTL, or (c) the an-
tibody binds to residues that are necessary forCTL recognition . While it is usually
difficult to distinguish between these alternatives, the observation that 28-14-8 did
notinhibit the activity of secondaryCTL indicated that this antibody did not cause
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Tteatrnent on d 02,4:
...-no Ab (15)
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Treatment weekly from d0:
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FIGURE 2 . Survival of BALB/c
skin grafts on dm2 recipients (Ld
disparate) given either no antibody,
0.2 ml ofmAb 28-14-8, 0.2 ml of
mAb 30-5-7, or a combination of
0.1 ml of28-14-8 and0.1 ml of 30-
5-7 for the times indicated starting
with the day of grafting. The con-
trol mAb ascites used was 3-83
(anti-H-2k) . The numbers in pa-
rentheses represent the number of
animals in each treatment group.
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FIGURE 3.
￿
Survival of Ld-disparate
(A) or Dd-disparate (B) skin grafts in
mice given antibodies to MHC class
I determinants. Animals received ei-
ther 0.2 ml of one antibody or 0.1 tnl
of both antibodies at the times indi-
cated startingwiththedayof grafting.
The numbersin parentheses represent
the number of animals in each treat-
ment group.
conformational changes in allodeterminants, nor a steric hindrance, for secondary
CTL activity. This finding also raised the possibility that the inhibition by 28-14-8
of primary CTL activity was because this antibody bound a determinant that was
recognized by primary CTL, but not by secondary CTL.
Antibodies to Either the al/a2 or the a3 Domain ofH-2Ld Inhibit the Generation ofPri-
mary CTL In Vitro. Having established that therewas a difference between primary
and secondary anti-Ld CTL in the susceptibility to inhibition by the a3 domain an-
tibody when added during the effector phase, we next examined the effect of anti-
bodies added during the sensitization phase. Addition of the 28-14-8 (a3 domain)
or the 30-5-7 (al/a2 domain) antibodies during the 5-d in vitro sensitization
abrogated the generation of Ld-specific primary CTL (Fig. 1 C). To examine
whether these antibodies would also inhibit the generation of secondary CTL we
tested the effect of antibodies added during in vivo priming.
Treatment with a Combination ofAntibodies to al/a2 and a3 Epitopes ofLd has a Syner-
gistic Effect on Skin Graft Enhancement. Priming ofCTL in vivo can be achieved either
by the injection ofallogeneic cell suspensions or by performing an allograft. We decided
to perform allografting as it allowed us to monitor the effect of antibodies on the
priming ofCTL, not only through the subsequent analysis ofprimed CTL popula-
tions, but also by the impact ofantibodies on the survival ofthe graft. The injection
ofantibodies to class II MHC molecules expressed on an allograft can be very effec-
tive in enhancing skin graft survival (23). As the antibodies to H-2Ld inhibited the
generation and the activity of CTL in vitro, a similar effect in vivo would enhance
the survival of H-2Ld-disparate skin grafts. To confine the disparity to H-2Ld, dm2
mice received a graft from BALE/c mice. Some of the skin-grafted animals were
injected with antibody to either the al/a2 domains (30-5-7), or the a3 domain
(28-14-8) of Ld or with both antibodies. Animals that received either of the two
antibodies on days 0, 2, and 4 showed a slight enhancement of skin graft survival
compared with animals that received no antibody or an irrelevant antibody (anti
H-2Kk) on days 0, 2, and 4 (Fig. 2 A). Graft survival was enhanced more when
animals received both antibodies together on days 0, 2, and 4 (Fig. 2 A). This finding
is consistent with a recent report by Lems et al. (24). Since both antibodies were
found to have a comparable in vivo half-life of N3 wk (cytotoxicity data not shown),
a regimen ofweekly antibody injections was also tested. When the injections ofanti-330
￿
Lyt-2 RECOGNIZES RESIDUES IN THE CLASS I a3 DOMAIN
so
W
40 20 10
EFFECTOR TO TARGET RATIO
FIGURE 4.
￿
In vitroLd-specific CTLresponses after
in vivo skin graft priming of animals treated with
graft-specific antibodies. Dm2 mice received 28-14-
8in vivo(0), 30-5-7 in vivo (A), or 28-14-8 + 30-5-
7 in vivo (/) at the time of grafting with BALB/c
skin. Spleen cells from each groupwere restimulated
in vitro with BALB/c spleen cells. P815 wasused as
thetarget cell andthespontaneous releasewas5.4%.
Unstimulated cellsfrom each groupwere included
and their Ld-specific lysis was zero.
body were given weekly, dramatic synergism between the two antibodies was ob-
served (Fig. 2 B). About 40% (11/25) of the mice that received both antibodies had
viable tissue grafts after 100 d. In contrast, mice that received only one of the H-2Ld
antibodies rejected their grafts before 24 d. A similar enhancement ofgraft survival
by treatment with both H-2Ld antibodies was also seen in (CM x dm2)Ft mice
grafted with BALB/c skin. In this experiment the injections of antibody were given
on days 0, 2, and 4 and the injection of both antibodies together enhanced the sur-
vival of the graft in these Ft mice even more than similarly timed injections given
to dm2 mice (Figs. 3 A and 2 A). The finding that enhancement appears easier to
obtain in the Fl mice as compared with dm2 mice could be accounted for by either
(a) a weaker anti-Ld response in the Fl due to elimination of H-2k-crossreactive CTL
clones or (b) the matching of Ig allotype/idiotype in the Ft since 28-14-8 is a C3H-
derived antibody. In addition to examining the effect of H-2Ld antibodies on the
survival of H-2Ld-disparate grafts we also investigated whether a combination of
antibodies to al/a2 and a3 H-2Dd determinants could enhance the survival of
H-2Dd-disparate grafts.
To confine the disparity to H-2Dd determinants, (C3H.OL x BALB.K)F1 recipi-
ents were grafted with dm2 skin. Some of these animals received either the 34-2-12
antibody (specific for a3 of Dd), or the 34-5-8 antibody (specific for al/a2 of Dd),
or a combination of the two antibodies on days 0, 2 and 4. Antibody to either the
al/a2 or a3 domains alone caused only slight enhancement of skin graft survival,
whereas a combination of the two antibodies had a synergistic effect and resulted
in prolonged graft survival (Fig. 3 B). This synergism between a1/a2 and a3 do-
main antibodies in the prolongation of either H-2Ld or H-2Dd-disparate skin grafts
demonstrated that regimens using combinations ofantibodies to class I can enhance
class I-disparate skin grafts. This finding is in contrast to previous studies in which
antibodies to class II but not class I antigens enhanced allograft survival (23). In
addition, these data raise the possibility that recognition of both the al/a2 and a3
domains of the class I molecule are involved in allograft rejection.
In Vitro Ld-speck CTL Responses of Mice Injected with Antibodies to H-2Ld.
￿
To
delineate the mechanism of the synergistic effect of these antibodies on skin graft
enhancement, antibody-treated mice were tested for the generation ofCTL in vitro.
Dm2 mice that were grafted with BALB/c skin (anti-Ld) and had received either
no antibody, one antibody, or both antibodies (28-14-8 and 30-5-7) were tested for
their ability to generate Ld-specific CTL in vitro. From animals treated with a single
antibody, cultures were initiated at least 3 wk after graft rejection, and from animals80
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FIGURE 5. Antibody blocking of Ld-specific
(dm2 anti-BALB/c) CTL generated from primary
and secondary in vitro cultures. The secondary
cultures were generated after skin graft priming
(C. Some of the skin-grafted animals received
28-14-8 on the day of grafting and weekly until
rejection (C) and 28-14-8 was also included in
some of the cultures from the antibody-treated
animals (D). The antibodies included inthe CTL
assay were 3-83-negative control (A), 28-14-8 (O),
30-5-7 ( "), and 53-6.7 (Q). Antibody 53-7.3 was
also included as a negative control and lysis in
the presence of this antibody was not different
from lysis in the presence of the 3-83 antibody
control. Unstimulated control cells from each
group were included and lysis was zero. Sponta-
neous release fromtheP815 target cells was 10.5%.
that received both antibodiescultures were initiated from mice thatpossessed aviable
graft at least 5 wk after grafting.
Spleen cells from mice treated with either 28-14-8 or 30-5-7, or both antibodies
together, generated anti-Ld CTL after in vitro stimulation. The CTL response of
skin-grafted animalsthat received 28-14-8 in vivo (Fig. 4)wasindistinguishable from
that ofskin-grafted animals that did not receive any antibody (datanot shown), but
was greaterthan the response from animals that received either 30-5-7 alone or to-
gether with 28-14-8 (Fig. 4). It is interesting that animals treated with both anti-
bodies and showing no visible sign of graft rejection were able to generate an in
vitro anti-Ld CTL response. In addition, discontinuation of the weekly antibody
treatments leads to rejection of the grafts (data not shown).
In Vivo and In Vitro Treatment with a3 Domain-specific mAb Enhances the Generation of
Lyt-2-independent CTL. The data presented in Figs. 1-4 suggest that antibodies to
either al/a2 or a3 H-2Ld determinants can blockthe in vitro generation ofalloreac-
tive CTL from nonimmune mice; however, both antibodies are required toprolong
skin graft survival in vivo. In addition, spleen cells from skin-grafted mice treated
with either, or both, of the H-2Ld antibodies, could be stimulated in vitro to
generate anti-Ld CTL. We therefore examined whether the addition of H-2Ld an-
tibodies in vitro would inhibit the generation ofanti-Ld CTL from antibody-treated,
skin-grafted mice. As shown in Figs. 5 (A and B) and i (A and B), antibody to the
a1/a2 domains completely inhibits lysis byboth primary and secondary CTL gener-
ated in the absence ofantibody. In contrast, the a3 domain antibody did not inhibit
secondary CTL (Figs. 5 B and 1 B) as effectively as it inhibited the activity of pri-
mary CTL (Figs. 5 A and 1 A). Secondary CTL from mice injected with the a3
domain antibody at the time of grafting were even less inhibited by 28-14-8 (Fig.
5 C) than secondary CTL from mice that were not injected with antibody (Fig. 5
B). The activity ofsecondary CTL generated in the presence of28-14-8both invivo
and in vitro was essentially noninhibitable by the addition of 28-14-8 (Fig. 5 D).
It is also interesting that the secondary CTL generated in the presence of28-14-8
in vivo were not totally inhibitable with the al/a2 domain antibody 30-5-7. This
suggestedeither thattheseCTLhave ahigher affinity than those derivedfrom animals
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Log Relative Fluorescence
FIGURE 6 .
￿
Expression ofH-2D'-specific de-
terminants defined bymAb 34-5-8 (al/a2 do-
main specific) andmAb34-2-12 (a3 domain
specific) on cells transfected withthewild-type
Dd gene (R8.15 Dd glu) and cells tlansfected
with the a3 mutantj ;d gene (R8.15 Dd lys) .
Antibody-treated cells were developed with
F(ab')2 fragment ofgoat anti-mouse IgG, Fc
specific. The background histograms repre-
sent fluorescence emitted from cells treated
only with the fluorescein-conjugated devel-
oping antibody.
not treated with antibody, or alternatively, that aminorCTL population can recog-
nize Ld in the presence of bound 30-5-7 . The effect of Lyt-2 antibody on the lysis
by theseCTL populations was also examined . It was found that although antibody
to Lyt-2 almost totally inhibited primaryCTL (Fig. 5 A), the antibody had less in-
hibitory effect on secondaryCTL (Fig . 5 B) and had very little effect on secondary
CTL generated in the presence of 28-14-8 in vivo and in vitro (Fig . 5 D) . These
results suggestedthat theaddition of 28-14-8 antibody favored the generation of Lyt-
2-independent, over Lyt-2-dependent, anti-Ld CTL.
Cells Expressing a Mutation in the a3 Domain Are Killed by Lyt-2-independent Secondary
CTL but not Lyt-2-dependent Primary CTL . The observation that antibodies to the
a3 domain enhanced the generation of Lyt-2-independent CTL raised the possi-
bility that the residues of the a3 domain bound by the 28-14-8 antibody also con-
tributed to the determinant recognized by the Lyt-2 molecule ofCTL. If so, then
Lyt-2-dependent CTL could not associate with target cells with antibody bound
to the a3 domain because the antibody would prevent binding by the Lyt-2 mole-
cule . In contrast, Lyt-2-independent CTL wouldnot be inhibitedby a3 domain an-
tibody, and in addition, could kill target cells that have lost the determinant recog-
nized by the Lyt-2 molecule .
Recently it was demonstrated that substitution of lysine for glutamic acid at res-
idue 227 in the a3 domain ofH-2Dd abrogates binding of the H-213d a3 domain
specific antibody, 34-2-12, and lysis by primary anti-DdCTL (13, 14). FMF anal-
ysis demonstrated that there was no quantitative difference in the level of H-2Dd
expression between cells transfected with the mutant (Dd lys) or the wild-type (Dd
glu) H-2Dd gene, as both cells bound an equivalent amount of the al/a2 domainv
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FIGURE 7.
￿
Antibody blocking of Dd-specific, (C3H.OL x BALB.K)F1 anti-dm2, CTL gener-
ated from primary and secondary in vitro cultures and tested on the cells transfected with the
wild-type or mutant H-2Dd gene. The secondarycultures were generatedafter in vivo skin graft
priming animals (B and F), some of which received 34-2-12 in vivo (C and G). Some of the cul-
tures from the antibody-treated animals contained 34-2-12 (D and H). (A-D) Lysis from cells
expressing wild-typeDd (88.15.28, Dd glu); (E-H) lysisfrom cells expressing thea3 mutant Dd
(88.15.29, Dd lys). Theantibodies included in theCTLassaywere 34-2-12 (O), 53-6.7 anti-Lyt-2
(p), and a control without antibody (A). Additional control antibodies included in the assay
were 30-5-7 and 53-7.3, both of which gave the same results as the control without antibody.
Unstimulated controls gave no lysis on either of thetarget cell lines. Spontaneous release from
88.15.28 was 9.8% and from 88.15.29 was 6.4%.
H-2Dd-specific antibody 34-5-8, (Fig. 6). This indicates that qualitative and not
quantitative differences account for the functional differences described below.
We therefore examined whether secondary anti-Dd CTL, generated in the pres-
ence of antibody to the a3 domain, could kill cells transfected with the mutant Dd
gene andwhether such CTLwere Lyt-2 independent. As shown in Fig. 7, primary
anti-D' CTL did not kill cells expressing the mutant H-2Dd gene, 88.15.29 (Fig.
7 E). Furthermore, the lysis of the cells expressing wild-type H-2Dd was inhibited
by antibody to the a3 domain of Dd (34-2-12) and by antibody to Lyt-2 (Fig. 7 A).
In contrast, secondary anti-Dd CTL generated in the presence of 34-2-12 in vivo
and in vitro killed cells expressing the mutant or the wild-type H-2Dd gene equally
well and this lysis was not inhibited by 34-2-12 and only weakly inhibited by anti-
body to Lyt-2 (Figs. 7, D and H). To generate this Lyt-2-independent CTL popula-
tion it was necessary to include the antibody in vitro since in vivo treatment alone
was insufficient (Figs. 7, Cand G). The observation that cells expressing the mutant
H-2Dd gene were killed by Lyt-2-independent CTL generated in a secondary re-
sponse, but were not killed by Lyt-2-dependent primary CTL, suggested that the
effect of the mutation in the H-2Dd gene was destruction of the determinant recog-
nized by Lyt-2. Consistent with this interpretation, lysis of88.15.28 by a subpopu-
lation of secondary CTL generated in the absence of antibody, was not inhibited
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EFFECTOR TO TARGET RATIO
FIGURE 8. The ability of cells
transfected with Dd glu or Dd lys
to stimulatea primaryin vitrore-
sponse. (C3H.OL x BALB.K)FI
spleen cells were stimulated in vitro
with either L.Dd glu (A) or L.D'
lys(O)and theresultingCTLpop-
ulations were assayed on R8.15.28
Dd glu (A) and R8.15.29Dd lys(B)
target cellsin thepresence (A, ")
or absence (A, O) of antibody to
Lyt-2. Spontaneous release from
R8.15.28 was 6.3% and from
R8.15.29 was 5.4%.
by antibody to 34-2-12 or anti-Lyt-2 (Fig. 7 B) and it is this subpopulation of CTL
that is capable of lysing the mutant R8.15.29 (Fig. 7 F).
Cells Expressing a Mutation in thea3 Domain Fail to Elicit a Primary In Vitro CTL Re-
sponse. The data presented thus far demonstrate that the Dd lys mutant is not rec-
ognized by primary CTL generated against the wild-type Dd glu molecule. How-
ever, the Dd lys molecule is recognized by anti-Dd CTL generated in secondary
responses to wild-type Dd, especially when they are generated in the presence of
mAb to the a3 domain. We thereforewanted to determinewhethera CTL response
could be generated using the Dd lys mutant as the stimulating antigen. If the mu-
tation in the a3 domain resulted in secondary conformational effects on the al/a2
domains that abrogated recognition by primary CTL, then the mutant Dd lys mol-
ecule should be capable of eliciting a CTL response specific forDd lys. If, however,
the mutation prevents a necessary interaction between Lyt-2 and the a3 domain for
the generation of primary in vitro CTL, then the Dd lys antigen might not stimu-
late a primary response in vitro.
To test whether Dd lys can stimulate a primary response, naive (C3H.OL x
BALB.K)F1 spleen cells were stimulated with irradiated L cells expressing thewild-
type (L.D' glu) or mutant (L.Dd lys) Dd molecule. This response is confined to
H-2D' since these FI responder spleen cells express antigens encoded by both the
C3H background and the H-2k haplotype. Thus the only determinants recognized
by the Ft responders on these L cell transfectants should be located on the Dd lys
or Dd glu molecule respectively. When analyzed by FMF, the L.Dd glu and L.Dd
lys transfectants expressed equivalent amounts ofDd molecule as measured by their
ability to bind the al/a2-reactive mAb 34-5-8 (data not shown). The Fl anti-L.Dd
effectors were tested on "Cr-labeled R8.15 transfectants, since these cells serve as
better targets than the L cell transfectants. As shown in Fig. 8 A, the wild-type Dd
glu molecule elicited a strong CTL response which was almost completely inhibited
by antibody to Lyt-2. Consistent with earlierfindings (Fig. 7and reference 14), these
anti Dd-glu effectors showed only weak cytotoxicity on mutant DI-lys antigens and
this lysis was not inhibited by anti-Lyt-2 (Fig. 8 B). In contrast, cells expressing the
mutant Dd lys molecules failed to stimulate a primary CTL response when assayed
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on cells expressing either the Dd lys or the Dd glu molecule (Fig . 8). This observa-
tion provides additional evidence that the a3 domain is involved in Lyt-2 recogni-
tion in primary CTL responses.
Discussion
Characterization of the TCR on subclasses of T cells has led to the observation
that the same Va and Vß chains can be used in receptors restricted by or specific
for class I or class II MHC products (25-29) . Since the distinction ofMHC class
by T cells cannot be explained by the usage of nonoverlapping TCR a and ß gene
pools, an additional feature ofthis interaction must provide the basis for the differential
recognition . TheT cell accessory molecules Lyt-2 (CD8)and L3T4(CD4) havebeen
implicated as playing a key role in distinguishing class I from class II molecules.
A stringent correlation exists between the T cell subset phenotype and the class of
MHC gene products recognized by the TCR . The Lyt-2'/CD8' T cells interact
with targets expressing class I MHC antigens and the L3T4''/CD4+ T cells interact
with targets expressing class II MHC antigens (11, 30-32) .
The functional involvement of the Lyt-2 surface antigen inT cell recognition of
class I was first recognized by the demonstration that antibody to Lyt-2 blocksCTL
activity (6, 7) . It was later proposed that the Lyt-2 receptor interacts with mono-
morphic determinants on theMHC class I molecules and thus facilitates low-affinity
interactions between the TCR and the class I molecule (11, 12) . Several reports pro-
vide evidence that L3T4/CD4 can enhance T cell responsiveness especially when
antigen is limiting and suggest that this is mediated, at least in part, by binding
L3T4/CD4 to the class II molecule (33-37) as proposed earlier (11) . Thus, both Lyt-
2 and L3T4 are thought to perform an adhesive function, facilitating theTCRMHC
interaction . However, it hasbecome increasingly evident that these accessory molecules
are involved with additional functions required for the regulation ofT cell activa-
tion that are independent ofMHC antigens (38-43) and that they may not always
be essential forT cell function (44). There is also recent evidence that activation
resultswhen CD4 or CD8 associates with the appropriate TCR on the cell surface
(45-48) . These studies also suggest that this is accomplished by the TCR and acces-
sory molecule binding to the same MHC molecule . Therefore, these accessory
molecules may facilitate T cell function through a multistep process, part of which
involves recognition of a monomorphic determinant on the MHC molecule .
SinceT cells that express the Lyt-2 phenotype are associated with class I recogni-
tion and antibodies to Lyt-2 can interfere with this recognition it is plausible that
the Lyt-2 molecule on the T cell interacts with amonomorphic determinant on the
class I molecule on the target cell, thus providing anMHC class I-specific recogni-
tion step . Here we present evidence that Lyt-2 recognizes a monomorphic deter-
minant in the a3 domain of the class I molecule and that this is a distinct site from
the one recognized by the TCR. Furthermore, our data suggest that mAb to class
I canbe used to specifically block either Lyt-2 orTCR recognition. These conclu-
sions are based on three lines of evidence . First, mAbs to the al/a2 and a3 class
Idomains show synergism in their ability toenhance Ld- or DI-disparate skin grafts.
Second, a correlation was foundbetween the ability ofmAb to a3 and Lyt-2 to block
in vitro CTL responses . Furthermore, mAb to a3 were used to skew the response336
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such that it was resistant to inhibition by mAb to a3 and correspondingly less in-
hibitable by antibody to Lyt-2. The third and most direct evidence supporting the
conclusion that Lyt-2 recognizes an a3 determinant is based on the experiments
using a cell line expressing a mutant Dd (R8.15Dd lys) that contains a single amino
acid substitution of glu to lys at residue 227 in the a3 domain . It is noteworthy that
position 227 ofclass I molecules is highly conserved, when comparing available se-
quences, not only in mice but in rat andhuman as well (compiled in reference 49).
Cells expressing the mutant R8.15 Dd lys molecule were not lysed by primaryCTL
generated against wild-type Dd molecules (13, 14 ; Fig. 7 E), and the weak lysis of
the mutant cell line observed in secondary responses to Dd (13, Fig. 7 F) was
significantly less inhibitable by mAb to a3 or Lyt-2 when compared with lysis on
controlR8.15 Dd glu targets. However, when mAb to a3 was used both in vivo and
in vitro, equal lysis ofmutant and wild-type targets by theseCTLwasobserved and
this lysis was not inhibited by antibody to a3 and was only slightly inhibited by an-
tibody to Lyt-2. Furthermore, cells expressing the mutant Dd lys molecule failed
to stimulate a primary CTL response. Therefore, these data suggest that the Dd
lys mutant has lost its ability to be recognized by Lyt-2 .
This conclusionwouldobviouslynot be justified ifsecondary effects resultingfrom
this mutation at position 227 influence the al/a2 TCR binding site. We feel this
possibility is highly unlikely for the following reasons. First, the binding of mAbs
to determinants in the al and/or a2 domains of the wild-type and mutant Dd
molecules is indistinguishable as measured by fluorometry (14, Fig . 6) . Second, T
cells whoserecognition is Lyt-2-independent, such as the hybridoma3DT52.5.8 (14)
or thebulkCTL culture shown in Fig . 7, give equal responses on mutant and wild-
type targets . Third, based on other structural comparisons, the distance separating
residue 227 from thepeptide binding site makes the possibility of a secondaryinter-
action unlikely . The recent three-dimensional structure of HLA-A2 revealed that
residue 227 is on the surface, but a considerable distance away from the peptide
binding site formed by the a1 and a2 domains (Dr . D . Wiley, personal communica-
tion) . The fourth and most direct evidence that the Dd lys mutation does not alter
TCR recognition of the al/a2 binding site is that cells expressing this mutation do
not elicit a primaryCTL response (Fig . 8) . If secondary conformational effects of
the mutation were responsible for the observed failure ofprimaryCTL to kill cells
expressing the mutant Dd molecule then cells expressing this mutant molecule
should stimulate a primary CTL response specific for theDd lys and not the Dd
glu molecule . As shown in Fig . 8, cells expressing the mutant Dd lys molecule, in
contrast to cells expressing theDd glu molecule, failed to elicit a primary response .
This result suggested that the Dd lys mutation affected a recognition site ofprimary
CTL that is distinct from the al/a2 site on class I molecules recognized by theTCR.
In total, these data strongly support the hypothesis that residue 227 is an integral
part of the Lyt-2 binding site on class I molecules.
The results reported here raise several interesting questions concerning in vivo
and in vitro recognition of class I molecules . For example, what is the nature of
the synergism that results when acombination of antibodies is used to prolong class
1-disparate graft survival since either antibody alonehasaminimaleffect? Theresults
of in vivo antibody blocking studies are obviously more complex since antibodies
to the al/a2 domain (30-5-7 for Ld) are clearly more proficient at abrogating theCONNOLLY ET AL .
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in vitro response than the in vivo response . This disparity is likely due to accessi-
bility and time constraint differences between the in vitro and in vivo assays . Per-
haps the in vivo situation allows enough time forCTL clones to be generated that
displace the antibody or recognize the class I molecule al/a2 domains in the pres-
ence ofbound antibody. Consistent with this conclusion arethemarked differences
seen in the ability of several different antibodies to blockthe in vitro response (50) .
Therefore, the relatively poor in vivo blocking of antibodies to al/CLL2, such as 30-5-
7, could be explained by the generation ofCTLclones capable of class I recognition
in thepresence ofantibody. Then thesynergism of antibody-induced graft enhance-
ment could be explained ifthese aforementioned CTLs are largely Lyt-2 dependent
and thus inhibitable with antibody to the a3 domain . Another question raised by
these studies is whether the Lyt-2+ T helper cell or the Lyt-2 + CTL (or both) is
blocked in vivo since both cell types appear to be involved in the rejection of skin
allografts differing at a single class I locus (51) . At the effector cell level, although
therewas a good correlation between inhibition by antibodies to a3 and Lyt-2, more
inhibition was consistently seen with antibodies to Lyt-2 than with antibodies to
a3 . This suggests that a function in addition to recognition is provided by the Lyt-
2/a3 interaction, such as signal transduction orTCR modulation (45, 46) . This in-
terpretation could also explain the partial inhibition of the lysis of cells expressing
the mutant Dd by antibodies to Lyt-2 (Fig . 7) .
In conclusion, the results reported here demonstrate thatmAbs to class I molecules
canbe used to selectively block distinctTcell recognition signals . Specifically, mAbs
to determinants in the a1/a2 domain blockTCR recognition, whereas mAbs to de-
terminants in the a3 domain block Lyt-2 recognition . This observation thus pro-
videsamethodwhereby specific siteson the ligand or class I molecule canbe blocked
to prevent either Lyt-2 orTCR recognition . For in vitro assays this observation can
be used to define the precise cellular andmolecular interactions involved in allogeneic,
and self-restricted hapten-specific or virus-specificT cell responses . For in vivo re-
sponses, our findings suggest that mAbto classI can be used to specifically abrogate
recognition of foreign tissue allografts . This blocking of in vivo recognition is in
contrast with most of the previous reports of allograft enhancement by antibodies
because it is mediated by antibodies to class I andnot class II molecules . Theextent
of prolongation of graft survival that we observed is also greater than that obtained
with antibodies to class II molecules . Furthermore, in the system reported here the
antibodies used forblocking are exclusively specific forantigens ofthe allograft and
notthehost . Thus, this approach is an exquisitely specific way to abolish recognition
of tissue transplants.
Summary
The involvement of the different domains of theMHC class I molecule in CTL
recognition was investigated . mAbs specific for the al/a2 domains of H-2Ld inter-
fered with both the primary and secondary generation and effector function of in
vitro Ld-specific CTL. mAbs specific for the a3 domain of H-2Ld interfered with
the generation and function of primary in vitro Ld-specificCTL; however, there was
no effect on the in vitro generation of secondaryCTL and only partial inhibition
oftheir function . In vivo treatment with graft-specific antibodies to both the a3 do-
main and the a1/a2 domains together resulted in a dramatic enhancement of Ld-338
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or Dd-disparate skin grafts, whereas the individual mAbs showed minimal effects.
This suggestedthat the class I a3 domain is recognized by alloreactive CTL. Several
approaches were undertaken to examine whetherrecognition ofthe a3 domain de-
terminants is mediated by the Lyt-2 molecule. When mAbs specific for the a3 do-
main ofeither H-2Ld or H-21)d were used in vivo and in vitro, the resulting CTL
population was not inhibited by antibody to the a3 domain and was only partially
inhibited by antibody to Lyt-2. We therefore observed a correlation between the
effects ofantibody to the class I a3 domain ofthe target molecule and antibody to
the Lyt-2 molecule on the CTL. To further test the relationship between CTL rec-
ognition ofthe a3 domain and the involvement of Lyt-2, we used a cell expressing
a mutation in the a3 domain ofthe Dd molecule. The mutation resulted in a single
amino acid substitution of glu to lys at residue 227 ofthe a3 domain. Consistent
with an earlier report, cells expressing the mutant Dd lys molecule were not lysed
by CTL from a primary stimulation against the wild-type Dd glu molecule. How-
ever, this same cell line was killed by the Lyt-2-independent secondary DI-specific
CTL generated in the presence ofantibody to the a3 domain in vivo and in vitro.
Furthermore, cells expressing the mutant Dd lys molecule failed to stimulate apri-
mary response. In conclusion, several independent lines of evidence indicate that
residues in the a3 domain ofthe class I molecule are involved in recognition by the
Lyt-2 molecule, and that Lyt-2-mediated recognitioncanbespecifically blockedusing
mAb to determinants in the 0 domain.
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